Interviews
View More
AI in Cancer Care Supporting Patients Enhancing Vaccines and Predicting Risks

Experts at City of Hope, Simon Nazarian and Nasim Eftekhari, discussed the transformative potential of AI in cancer care.

Preserving Beta Cell Function in T1D: Current Strategies and Emerging Therapies

A panelist discusses how preserving beta-cell function in type 1 diabetes (T1D) requires a multifaceted approach combining timely diagnosis, immunomodulatory therapies, optimal glycemic control and emerging technologies that can slow disease progression and improve patient outcomes.

Interview with Aaron B. Waxman, MD, PhD: How recent developments in pulmonary arterial hypertension impact managed healthcare: part 2
Interview with Aaron B. Waxman, MD, PhD: How recent developments in pulmonary arterial hypertension impact managed healthcare: part 1
Why GLP-1 Drugs Alone Aren’t Enough for Lasting Weight Loss

In a recent conversation with Managed Healthcare Executive, Geoffrey Rutledge, M.D., of HealthTap, warned that the narrative around GLP-1 drugs is often oversimplified—and potentially harmful.

Important Takeaways Regarding the Utilization of Ruxolitinib

Panelists discuss how ruxolitinib offers significant advantages in atopic dermatitis management through its targeted JAK inhibition mechanism, demonstrating rapid and sustained improvement in itch and lesions, effectiveness across various disease severities and body regions, favorable safety profile compared to systemic alternatives, and potential for reduced healthcare resource utilization over extended treatment periods.

Closing Insights: The Future of Cemiplimab in NSCLC and Beyond

Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers like non-small cell lung cancer (NSCLC) is expected to evolve toward more personalized, targeted approaches. This will enhance survival outcomes, refine patient selection and optimize therapy regimens.

Misdiagnosis of Type 1 Diabetes in Adults: Prevalence, Causes and Consequences

A panelist discusses how type 1 diabetes (T1D) is frequently misdiagnosed in adults due to its overlapping clinical features with type 2 diabetes (T2D), resulting in inappropriate treatment strategies that fail to address the autoimmune destruction of beta cells and lead to accelerated disease progression and complications.

The Role of Continuing Cemiplimab in Second-Line Therapy After Progression

Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after progression on prior treatments. Continuing cemiplimab post-progression can enhance survival outcomes by maintaining immune system activation against cancer cells.

Official Media Partners